View More Recent Stories

Oct 11, 2017 08:02AM Seattle Genetics (SGEN) Reports Clinical Collaboration Agreements to Evaluate SGN-LIV1A
Oct 11, 2017 08:00AM Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer
Oct 10, 2017 08:06AM Seattle Genetics (SGEN) & Astellas Commences Pivotal Trial of Enfortumab Vedotin
Oct 10, 2017 08:00AM Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Oct 10, 2017 08:00AM Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Oct 10, 2017 06:50AM Seattle Genetics (SGEN) & Genmab Commences New Study Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
Oct 10, 2017 06:44AM Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
Jun 15, 2017 07:00AM Seattle Genetics (SGEN) and Bristol-Myers Squibb (BMY) Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS (Brentuximab Vedotin) & Opdivo (Nivolumab)
Jun 15, 2017 06:58AM Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the Inter
Jun 5, 2017 10:48AM Seattle Genetics (SGEN), Astellas Announce Updated Enfortumab Vedotin Phase 1 Data in mUC at ASCO
Jun 5, 2017 10:45AM Seattle Genetics and Astellas Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting
Jun 5, 2017 10:45AM Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting
Jun 2, 2017 06:03AM Bristol-Myers Squibb (BMY) & Seattle Genetics (SGEN) Announce Expanded Collaboration to Evaluate Combination of Opdivo (Nivolumab) & ADCETRIS (Brentuximab Vedotin) in Phase 3 Clinical Trial
Jun 2, 2017 06:00AM Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and ADCETRIS® (Brentuximab Vedotin) in Pivotal Phase 3 Clinical Trial in Relapsed
Feb 10, 2017 09:30AM Pre-Open Movers 02/10: (SHLD) (ICPT) (IMMU) Higher; (ONVO) (RSYS) (TCON) Lower (more...)
Dec 6, 2016 06:18AM Seattle Genetics (SGEN), Bristol-Myers (BMY) Present First Data from ADCETRIS + Opdivo Phase 1/2 in r/r HL
Dec 5, 2016 07:30PM Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin
Oct 26, 2016 02:46PM Trading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), Baidu.com (BIDU) Report
Jul 25, 2016 02:40PM Trading Radar for 7/26: Apple (AAPL), McDonald's (MCD), 3M (MMM), Caterpillar (CAT), Verizon (VZ), [Conference Call] Under Armour (UA) Report
Dec 23, 2015 08:01AM Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY) Initiate ADCETRIS + Opdivo Phase 1/2 in DLBCL
Dec 23, 2015 08:00AM Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hod
Dec 6, 2010 09:02AM Ariad (ARIA) May Have Been Best at ASH Meeting
View More Recent Stories